TVTX Travere Therapeutics, Inc.

NASDAQ
$59.44

Travere Therapeutics, Inc. (TVTX) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.1% since its last earnings release on August 4, 2026.

Travere Therapeutics Missed Consensus Estimates
Tuesday, August 4, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:00 PM ET
Earnings Whisper
-
vs $0.05
Rev est $191.8M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $63.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Travere Therapeutics, Inc.

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.